Tear Trough Rejuvenation With Injectable Biostimulatory Polynucleotides (VAMP)

Tear trough rejuvenation presents a clinical challenge due to thin skin, superficial vasculature, and age-related volume loss. VAMP, manufactured by Prollenium, a polynucleotide-based biostimulatory injectable, is designed to support dermal regeneration and improve skin quality without volumizing excess. The objective of this study was to evaluate early clinical outcomes after VAMP injection in the tear trough area. Five healthy female patients (aged 35-50 y) of Middle Eastern and White descent were treated with 2 mL of VAMP (1 mL per side) using a 23G 30-mm SoftFil microcannula. The product was delivered via a combined microdroplet and linear threading technique to enhance distribution. Follow-up assessments were conducted at 1 week, 2 weeks, 1 month, and 3 months. Evaluation included standardized clinical photography, patient-reported satisfaction, and assessments of texture, tone, pigmentation, and contour. Mild to moderate improvements were observed in tear trough appearance, skin smoothness, and pigmentation. No adverse events were reported within the follow-up period. However, the limited sample size and short duration preclude definitive conclusions. Preliminary results suggested that VAMP may offer a promising option for tear trough rejuvenation. Further studies with larger cohorts and extended follow-up beyond 6 months are warranted.